

Onconova Therapeutics, Inc.  
Form 4  
August 01, 2013

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
MEHTA VIREN

2. Issuer Name and Ticker or Trading Symbol  
Onconova Therapeutics, Inc.  
[ONTX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
07/30/2013

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O ONCONOVA THERAPEUTICS, INC., 375 PHEASANT RUN

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

NEWTOWN, PA 18940

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
			Code	V	Amount or Price (A) or (D)		
Common Stock	07/30/2013		C		73,839 <sup>(2)</sup>	A	<u>(1)</u> 85,479 <sup>(2)</sup> D
Common Stock	07/30/2013		C		7,686	A	<u>(8)</u> 93,165 <sup>(2)</sup> D
Common Stock	07/30/2013		C		17,082 <sup>(10)</sup>	A	<u>(9)</u> 110,247 <sup>(2)</sup> <sup>(10)</sup> D
Common Stock	07/30/2013		P		16,667	A	\$ 15 <u>(10)</u> 126,914 <sup>(2)</sup> D
	07/30/2013		C		6,768	A	<u>(1)</u> 6,768 I

Edgar Filing: Onconova Therapeutics, Inc. - Form 4

Common Stock								By Viram Foundation <u>(3)</u>
Common Stock	07/30/2013	C	772	A	<u>(6)</u>	7,540	I	By Viram Foundation <u>(3)</u>
Common Stock	07/30/2013	C	755	A	<u>(7)</u>	8,295	I	By Viram Foundation <u>(3)</u>
Common Stock	07/30/2013	C	4,632	A	<u>(1)</u>	4,632	I	By Mehta Partners LLC <u>(4)</u>
Common Stock	07/30/2013	C	1,702	A	<u>(6)</u>	6,334	I	By Mehta Partners LLC <u>(4)</u>
Common Stock	07/30/2013	C	1,722	A	<u>(7)</u>	8,056	I	By Mehta Partners LLC <u>(4)</u>
Common Stock	07/30/2013	C	1,050	A	<u>(1)</u>	1,050	I	By Mehta Partners LLC FBO Jean Kiss Marie IRA <u>(5)</u>
Common Stock	07/30/2013	C	345	A	<u>(6)</u>	1,395	I	By Mehta Partners LLC FBO Jean Kiss Marie IRA <u>(5)</u>
Common Stock	07/30/2013	C	338	A	<u>(7)</u>	1,733	I	By Mehta Partners LLC FBO Jean Kiss Marie IRA <u>(5)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Onconova Therapeutics, Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Convertible Preferred Stock	<u>(1)</u>	07/30/2013		C	87,470 <u>(11)</u>	<u>(1)</u>	<u>(1)</u>	Common Stock	73,839 <u>(2)</u>
Series E Convertible Preferred Stock	<u>(8)</u>	07/30/2013		C	10,246	<u>(8)</u>	<u>(8)</u>	Common Stock	7,686
Series I Convertible Preferred Stock	<u>(9)</u>	07/30/2013		C	22,771 <u>(12)</u>	<u>(9)</u>	<u>(9)</u>	Common Stock	17,082 <u>(12)</u>
Series B Convertible Preferred Stock	<u>(1)</u>	07/30/2013		C	8,020	<u>(1)</u>	<u>(1)</u>	Common Stock	6,768
Series C Convertible Preferred Stock	<u>(6)</u>	07/30/2013		C	1,030	<u>(6)</u>	<u>(6)</u>	Common Stock	772
Series D Convertible Preferred Stock	<u>(7)</u>	07/30/2013		C	1,007	<u>(7)</u>	<u>(7)</u>	Common Stock	755
Series B Convertible Preferred Stock	<u>(1)</u>	07/30/2013		C	5,488	<u>(1)</u>	<u>(1)</u>	Common Stock	4,632
Series C Convertible Preferred Stock	<u>(6)</u>	07/30/2013		C	2,270	<u>(6)</u>	<u>(6)</u>	Common Stock	1,702
Series D Convertible Preferred Stock	<u>(7)</u>	07/30/2013		C	2,296	<u>(7)</u>	<u>(7)</u>	Common Stock	1,722



## Edgar Filing: Onconova Therapeutics, Inc. - Form 4

- (9) The Series I Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (10) Includes 17,082 shares held jointly with spouse.
- (11) Includes 13,454 shares held jointly with spouse.
- (12) Shares held jointly with spouse.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.